Bac Viet Le, Umeshkumar Vekariya, Monika M. Toma, Margaret Nieborowska-Skorska, Marie-Christine Caron, Malgorzata Gozdecka, Zayd Haydar, Martin Walsh, Jayashri Ghosh, Elaine Vaughan-Williams, Paulina Podszywalow-Bartnicka, Anna-Mariya Kukuyan, Sylwia Ziolkowska, Jessica Atkins, Emir Hadzijusufovic, Gurushankar Chandramouly, Reza Nejati, Katarzyna Piwocka, Richard Pomerantz, George S. Vassiliou, Brian J.P. Huntly, Peter Valent, Mariusz Wasik, Alfonso Bellacosa, Jean-Yves Masson, Gaorav P. Gupta, Grant A. Challen, Tomasz Skorski. Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia, Cell Reports Medicine, Volume 7, Issue 3, 2026, 102687, ISSN 2666-3791, https://doi.org/10.1016/j.xcrm.2026.102687.
Toma MM, Karami A, Nieborowska-Skorska M, Skorski T. Clonal composition of karyotypically normal AML at diagnosis is not affected by the microenvironment. Blood Neoplasia. 2025 Jan 25;2(2):100073. doi: 10.1016/j.bneo.2025.100073. PMID: 40453148; PMCID: PMC12067891.
Atkins J, Kukuyan AM, Toma M, Drzewiecka M, Vekariya U, Karami A, Nieborowska-Skorska M, Nejati R, Hadzijusufovic E, Valent P, Stoklosa T, Sliwinski T, Wasik M, Skorski T. ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications. Leukemia. 2025 Sep;39(9):2152-2162. doi: 10.1038/s41375-025-02687-3. Epub 2025 Jul 10. PMID: 40640557; PMCID: PMC12380611.
Abhinav Ayyadevara VSS, Gaur S, Paik A, Perencsik R, Toma M, Wertheim G, Geng H, Skorski T, Swaminathan S, Hurtz C. Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy. bioRxiv [Preprint]. 2025 Jul 11:2025.07.08.661805. doi: 10.1101/2025.07.08.661805. PMID: 40672274; PMCID: PMC12265558.
Li H, Chatla S, Liu X, Tian Z, Vekariya U, Wang P, Kim D, Octaviani S, Lian Z, Morton G, Feng Z, Yang D, Sullivan-Reed K, Childers W, Yu X, Chitrala KN, Madzo J, Skorski T, Huang J. ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025 Mar 31;613:217505. doi: 10.1016/j.canlet.2025.217505. Epub 2025 Jan 31. PMID: 39892701.
C.W. Schultz, S. Saha, A. Dhall, Y. Zhang, P. Desai, L.S. Pongor, D.A. Scheiblin, V. Magidson, R.P. Shuklah, R. Sebastian, U.M. Vekariya, S. Ahmed, Y. Sun, C. Redon, S. Kumar, M. Krishnamurthy, H.B. Dias, V. Aksenova, E. Giordano, N. Takahashi, M. Nirula, M. Arora, C. Tabe, M.S. Thomas, R. Kumar, Y. Arakawa, U. Jo, T. Skorski, B.A. Teicher, R. Shreshta, M.I. Aladjem, S. Lockett, M. Dasso, Y. Pommier, A.K. Sharma, & A. Thomas, Lamin A/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer, Proc. Natl. Acad. Sci. U.S.A. 122 (43) e2503387122, https://doi.org/10.1073/pnas.2503387122 (2025).
Gurushankar Chandramouly, William Fried, John Gordon, Douglas Ralph, Channita Keuk, Sangeeta Kumari, Mercy Ramanjulu, William Auerbacher, Leonid Minakhin, Taylor Tredinnick, Bernadette Tiberi, George Morton, Robert Betsch, Kathy Q. Cai, Umeshkumar M. Vekariya, Mrityunjay Tyagi, Tomasz Skorski, Sergey Karakashev, Neil Johnson, Wayne E. Childers Jr, Xiaojiang S. Chen, and Richard T. Pomerantz Journal of Medicinal Chemistry Article ASAP DOI: 10.1021/acs.jmedchem.5c00551
Toma, M.M., Karami, A., Nieborowska-Skorska, M. et al. Clonal medicine targeting DNA damage response eradicates leukemia. Leukemia 38, 671–675 (2024). https://doi.org/10.1038/s41375-024-02138-5
Calbert ML, Chandramouly G, Adams CM, Saez-Ayala M, Kent T, Tyagi M, Ayyadevara VSSA, Wang Y, Krais JJ, Gordon J, Atkins J, Toma MM, Betzi S, Boghossian AS, Rees MG, Ronan MM, Roth JA, Goldman AR, Gorman N, Mitra R, Childers WE, Graña X, Skorski T, Johnson N, Hurtz C, Morelli X, Eischen CM, Pomerantz RT. 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Mol Cancer Ther. 2024 May 2;23(5):683-699. doi: 10.1158/1535-7163.MCT-23-0487. PMID: 38064712; PMCID: PMC11286238.
Liu ZS, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphapphaiboon W, Leibson C, McMahon MC, Rai S, Swisher EM, Sachs Z, Chatla S, Stirewalt DL, Deeg HJ, Skorski T, Papapetrou EP, Walter MJ, Graubert TA, Doulatov S, Lee SC, Nguyen HD. R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts. Cancer Res. 2024 Feb 15;84(4):577-597. doi: 10.1158/0008-5472.CAN-23-3239. PMID: 37967363; PMCID: PMC10922727.
Barszczewska-Pietraszek G, Czarny P, Drzewiecka M, Błaszczyk M, Radek M, Synowiec E, Wigner-Jeziorska P, Sitarek P, Szemraj J, Skorski T, Śliwiński T. Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells. Int J Mol Sci. 2024 Aug 23;25(17):9134. doi: 10.3390/ijms25179134. PMID: 39273083; PMCID: PMC11395082.
Le BV, Vekariya U, Toma MM, Nieborowska-Skorska M, Caron MC, Gozdecka M, Haydar Z, Walsh M, Ghosh J, Vaughan-Williams E, Podszywalow-Bartnicka P, Kukuyan AM, Ziolkowska S, Hadzijusufovic E, Chandramouly G, Piwocka K, Pomerantz R, Vassiliou GS, Huntly BJ, Valent P, Bellacosa A, Masson JY, Gupta GP, Challen GA, Skorski T. DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells. bioRxiv [Preprint]. 2024 Sep 19:2024.09.15.613155. doi: 10.1101/2024.09.15.613155. PMID: 39411165; PMCID: PMC11475869.
Toma, M.M., Skorski, T. Star wars against leukemia: attacking the clones. Leukemia 38, 2293–2302 (2024). https://doi.org/10.1038/s41375-024-02369-6
Ito F, Li Z, Minakhin L, Chandramouly G, Tyagi M, Betsch R, Krais JJ, Taberi B, Vekariya U, Calbert M, Skorski T, Johnson N, Chen XS, Pomerantz RT. Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM. Nat Commun. 2024 Aug 14;15(1):7003. doi: 10.1038/s41467-024-51351-4. PMID: 39143110; PMCID: PMC11324745.
Vekariya, U., Minakhin, L., Chandramouly, G. et al. PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks. Nat Commun 15, 5822 (2024). https://doi.org/10.1038/s41467-024-50158-7.
Karami, A., Skorski, T. DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients. Leukemia 38, 1407–1410 (2024). https://doi.org/10.1038/s41375-024-02269-9.
Fried, W., Tyagi, M., Minakhin, L. et al. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors. Nat Commun 15, 2862 (2024). https://doi.org/10.1038/s41467-024-46593-1.
Gray ZH, Chakraborty D, Duttweiler RR, Alekbaeva GD, Murphy SE, Chetal K, Ji F, Ferman BI, Honer MA, Wang Z, Myers C, Sun R, Kaniskan HÜ, Toma MM, Bondarenko EA, Santoro JN, Miranda C, Dillingham ME, Tang R, Gozani O, Jin J, Skorski T, Duy C, Lee H, Sadreyev RI, Whetstine JR. Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement. Cell 2023;186(21):4528-4545 PMID: 37788669.
Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T. Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. J Pers Med. 2023;13(9):1315. PMID: 37763083.
Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jaśniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyż M, Skorski T, Śliwiński T. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. Genes (Basel). 2023;14(6):1295. PMID: 37372475.
Sullivan-Reed K, Toma MM, Drzewiecka M, Nieborowska-Skorska M, Nejati R, Karami A, Wasik MA, Sliwinski T, Skorski T. Simultaneous targeting of DNA polymerase theta and PARP1 or RAD52 triggers dual synthetic lethality in homologous recombination-deficient leukemia cells. Mol Cancer Res. 2023; 21(10):1017-1022. PMID: 37358557.
Wolczyk M, Serwa R, Kominek A, Klejman A, Milek J, Chwałek M, Turos-Korgul L, Charzyńska A, Dabrowski M, Dziembowska M, Skorski T, Piwocka K, Podszywalow-Bartnicka P. TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment. iScience. 2023;26(4):106543.PMID: 37123244.
Golovine K, Abalakov G, Lian Z, Chatla S, Karami A, Chitrala KN, Madzo J, Nieborowska-Skorska M, Huang J, Skorski T. ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemia. Blood Cancer J. 2023 23;13(1):42. PMID: 36959186.
Barszczewska-Pietraszek G, Drzewiecka M, Czarny P, Skorski T, Śliwiński T. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. Int J Mol Sci. 2022;24(1):319.
Le BV, Podszywałow-Bartnicka P, Piwocka K, Skorski T. Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. Cancers (Basel). 2022;14(23):5795.
Vekariya U, Toma MM, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik MA, Sykes S, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta E, Levine RL, Tallman MS, Fernandez H, Litzow MR, Gupta G, Masson JY, Skorski T. DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage. Blood. 2023;141(19):2372-2389.PMID: 36580665.
Drzewiecka M, Barszczewska-Pietraszek G, Czarny P, Skorski T, Śliwiński T. Synthetic Lethality Targeting Polθ. Genes (Basel), 2022 Jun 20;13(6):1101. PMID: 35741863.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol. Oncol. 2022 Apr 3. Online ahead of print. PMID: 35368098.
Swatler J, Turos-Korgul L, Brewinska-Olchowik M, De Biasi S, Dudka W, Le BV, Kominek A, Cyranowski S, Pilanc P, Mohammadi E, Cysewski D, Kozlowska E, Grabowska-Pyrzewicz W, Wojda U, Basak G, Mieczkowski J, Skorski T, Cossarizza A, Piwocka K. 4-1BBL-containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells. Blood Adv., 2022 Mar 22;6(6):1879-1894. PMID: 35130345.
Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, Bartholdy BA, Matlawska-Wasowska K, Di Marcantonio D, Simonetti G, Greiner G, Sykes SM, Valent P, Paietta EM, Tallman MS, Fernandez HF, Litzow MR, Minden MD, Huang J, Martinelli G, Vassiliou GS, Tempera I, Piwocka K, Johnson N, Challen GA, Skorski T. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Res. 2021 Oct 1;81(19):5089-5101. PMID: 34215619.
Chandramouly G, Liao S, Rusanov T, Borisonnik N, Calbert ML, Kent T, Sullivan-Reed, K, Vekariya U, Kashkina E, Skorski T, Yan H, Pomerantz RT. Polθ promotes the repair of 5'-DNA-protein crosslinks by microhomology-mediated end-joining. Cell reports 2021;34:108820. PMCID: PMC8565190.
Di Marcantonio D, Martinez E, Kanefsky JS, Huhn JM, Gabbasov R, Gupta A, Krais JJ, Peri S, Tan Y, Skorski T, Dorrance A, Garzon R, Goldman AR, Tang HY, Johnson N, Sykes SM. ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. Mol Cell. 2021 Jul 1;81(13):2752-2764. PMID: 34081901.
Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao J-C, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. TGFβR–SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment. Cell Rep., 2020 Oct 6;33(1):108221.
Hewlett E, Toma M, Sullivan-Reed K, Gordon J, Sliwinski T, Childers WE, Skorski T. Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. Med. Chem. Res., 2020, in press.
Nieborowska-Skorska M, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Skorski T. Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. Blood Adv. 2019 Dec 10;3(23):4050-4054.
Kirschner M, Bornemann A, Schubert C, Gezer D, Kricheldorf K, Isfort S, Brümmendorf TH, Schemionek M, Chatain N, Skorski T, Koschmieder S. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms. Ann Hematol. 2019 Dec;98(12):2703-2709.
Toma M, Sullivan-Reed K, Śliwiński T, Skorski T. RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies. Cancers (Basel). 2019 Oct 14;11(10):1561.
Flis S, Bratek E, Chojnacki T, Piskorek M, Skorski T. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells. Cancers (Basel). 2019 Oct 12;11(10):1544.
Black SJ, Ozdemir AY, Kashkina E, Kent T, Rusanov T, Ristic D, Shin Y, Suma A, Hoang T, Chandramouly G, Siddique LA, Borisonnik N, Sullivan-Reed K, Mallon JS, Skorski T, Carnevale V, Murakami KS, Wyman C, Pomerantz RT. Molecular basis of microhomology-mediated end-joining by purified full-length Polθ. Nat Commun. 2019 Sep 27;10(1):4423.
Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz AB, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochem Pharmacol. 2019 Sep;167:149-162.
Piwocka K, Podszywałow-Bartnicka P, Skorski T.Piwocka K. BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters. Postepy Biochem. 2018 Oct 15;64(2):141- 147.
Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska- Skorska M, Radek M, Kolasa P, Matlawska-Wasowska K, Sliwinski T, Skorski T. Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent. Oncotarget. 2018 Dec 7;9(96):36867-36877.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018 Jul 5;132(1):67-77.
Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska- Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep. 2018 Jun 12;23(11):3127-3136.
Podszywalow-Bartnicka P, Maifrede S, Le BV, Nieborowska-Skorska M, Piwocka K, Skorski T. PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions. Leuk Lymphoma. 2018 [Epub ahead of print].
Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leuk Lymphoma. 2018 Oct 2:1-4.
Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I. Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget. 2018 Jan 24;9(12):10585-10605.
Toma M, Skorski T, Sliwinski T. DNA double strand break repair - related synthetic lethality. Curr Med Chem. 2018 Jan 31.
Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Adv. 2017 Aug 9;1(19):1467-1472.
Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res. 2018 Feb 1;24(3):608-618.
Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T. Drugging DNA repair to target T-ALL cells. Leuk Lymphoma. 2017 Nov 8:1-4.
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 Dec 28;130(26):2848-2859.
Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors. Mol Cancer Res. 2017 Aug;15(8):967-972.
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017 Jun 1;127(6):2392-2406.
Mukherjee K, Sha X, Magimaidas A, Maifrede S, Skorski T, Bhatia R, Hoffman B, Liebermann DA. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia. Oncotarget. 2017 Feb 14;8(7):10809-10821.
Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Skorski T, Białas AJ, Sakowicz T, Kowalczyk T, Radek M, Wysokińska H, Śliwiński T. Transformed Root Extract of Leonurus sibiricus Induces Apoptosis through Intrinsic and Extrinsic Pathways in Various Grades of Human Glioma Cells. Pathol Oncol Res. 2017 Jul;23(3):679-687.
Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017 May;31(5):1196-1205.
Podszywalow-Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska- Skorska M, Koromilas AE, Skorski T, Piwocka K. Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes. Oncotarget. 2016 Nov 29;7(48):79706-79721.
Skała E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokińska H, Śliwiński T. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. J Pharm Pharmacol. 2016 Nov;68(11):1454-1464.
Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Nov 15;7(46):75551-75560.
Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Res. 2016 May 19;44(9):4189-99.
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.
Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. PLoS One. 2016 Jan 19;11(1):e0147230.
Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T. Mitochondrial mutagenesis in BCR-ABL1-expressing cells sensitive and resistant to imatinib. Acta Biochim Pol. 2016;63(2):365-70.
Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Nieborowska-Skorska M, Kolasa M, Skorski T, Wysokińska H, Śliwiński T. A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L. Tumour Biol. 2016 Jul;37(7):8753-64.
Synowiec E, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T, Blasiak J. Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib. Biomed Res Int. 2015;2015:673512.
Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chem Biol. 2015 Nov 19;22(11):1491-1504.
Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T. Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib. Biores Open Access. 2015 Jul 1;4(1):334-42.
Synowiec E, Hoser G, Wojcik K, Pawlowska E, Skorski T, Błasiak J. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib. Int J Mol Sci. 2015 Aug 5;16(8):18111-28.
Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska- Skorska M, Dasgupta Y, Skorski T, Piwocka K. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell Cycle. 2014;13(23):3727-41.
Nieborowska-Skorska M, Flis S, Skorski T. AKT-induced reactive oxygen species generate imatinib- resistant clones emerging from chronic myeloid leukemia progenitor cells. Leukemia. 2014 Dec;28(12):2416-8.
Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti- Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post- ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma, 54:1151-8, 2013.
Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 122:1293-304, 2013.
Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia, 11:2253-2254, 2013.
Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood, 121:4175-83, 2013.
Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia, 27:629-34, 2013.
Flis K, Irvine D, Copland M, Bhatia R, Skorski T. Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leuk, Lymphoma, 53:2474-8, 2012.
Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MR, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T. Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 119: 4253-63, 2012.
Skorski, T. BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem Biol., 18:1352-3, 2011.
Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood, 118:1062-8, 2011.
Falinski R, Nieborowska-Skorska M, Skorski T. BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks. Leuk Res., 36:241-4, 2012.
Skorski, T. BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem Biol., 18:1352-3, 2011.
Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol., 86:811-9, 2011.
Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, Skorski T. Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. Cancer Res., 71:5381-6, 2011.
Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood, 118:1062-8, 2011.
Koptyra M, Stoklosa T, Hoser G, Glodkowska-Mrowka E, Seferynska I, Klejman A, Blasiak J, Skorski T. Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis. Leukemia, 25:1259-67, 2011.
Skorski, T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable ticking time-bombs eventually exploding to cause disease relapse and malignant progression. Leukemia & Lymphoma, 52 Suppl 1:23-9, 2011.
Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, Nowicki MO, Blasiak J, Skorski T. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res., 71:842-51. 2011.
Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest., 120:2254-64, 2010.
Slupianek, A., Jozwiakowski SK, Gurdek E, Skorski T. BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B. Leukemia, 23:2308-2310, 2009.
Cramer, K., Nieborowska-Skorska, M., Koptyra, M., Slupianek, A., Penserga, ET., Eaves, CJ., Aulitzky, W, Skorski, T. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res., 68: 6884-6888, 2008.
Koptyra, M., Cramer, K., Slupianek, A., Richardson, C., Skorski, T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia, 22: 1969-1972, 2008.
Stoklosa, T., Poplawski, T., Koptyra, M., Nieborowska-Skorska, M., Basak, G., Slupianek, A., Rayevskaya, M., Seferynska, I., Herrera, L., Blasiak, J., Skorski, T. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 68 :2576-2580, 2008.
Skorski, T. BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts. Leukemia & Lymphoma, 49: 610-614, 2008.
Mughal T. Cortes J. Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia – some topical issues. Leukemia, 21:1347- 1352, 2007.
Rink, L., Slupianek, A., Stoklosa, T., Nieborowska-Skorska, M., Urbanska, K., Seferynska, I., Reiss, K., Skorski, T. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex RAD50-Mre11-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL- positive leukemia cells. Blood, 110:651-660, 2007.
Penserga, E.T.P., Skorski, T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene, 26:11-20, 2007.
Koptyra, M., Falinski, R., Nowicki, M.O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., Blasiak, J., Skorski, T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 108: 319-327, 2006.
Nieborowska-Skorska, M., Stoklosa, T., Datta, M., Czechowska, A., Rink, L., Slupianek, A., Koptyra, M., Seferynska, I., Krszyna, K., Blasiak, J., Skorski, T. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle, 5: 994-1000, 2006.
Nieborowska-Skorska, M., Hoser, G., Rink, L., Malecki, M, Kossev, P.,Wasik, M.A., Skorski, T. Id1 transcription inhibitor/MMP9 metalloproteinase axis enhances invasiveness of the BCR/ABL- transformed leukemia cells. Cancer Res., 66: 4108-4116, 2006.
Majsterek, I, Sliwinski, T., Poplawski, T., Pytel, D., Kowalski, M., Slupianek, A., Skorski, T. and Blasiak, J. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat Res., 603: 74-82, 2006.
Slupianek, A., Nowicki, M.O., Koptyra, M. and Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair, 5: 243-50, 2006.
Trojanek, J., Croul, S., Ho, T., Wang, J.Y., Darbinyan, A., Nowicki, M., Valle, L.D., Skorski, T., Khalili, K. and Reiss, K. T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. J Cell Physiol., 206: 35-46, 2006.
Ren, SY., Xue, F., Feng, J. and Skorski, T. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Exp. Hematol., 33: 1222-1228, 2005.
Slupianek, A., Gurdek, E., Koptyra, M., Nowicki, M.O., Siddiqui, K.M., Groden, J. and Skorski, T. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin. Oncogene, 24: 3914-3922, 2005.
118. Ren, SY., Bolton, E., Mohi, M.G., Neel, B.G. and Skorski, T. Phosphatidylinositol 3-kinase p85a subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol. Cell. Biol., 25: 8001-8008, 2005.
Wang, J.Y., Ho, T., Trojanek, J., Chintapali, J., Grabacka, M., Stoklosa, T., Garcia, F.U., Skorski, T. and Reiss, K. Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence. Oncogene, 24: 3748-3758, 2005.
Slupianek, A. and Skorski, T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Exp. Hematol., 32: 1265-1271, 2004.
Stoklosa, T., Slupianek, A., Datta, M., Nieborowska-Skorska, M., Nowicki, M.O., Koptyra, M. and Skorski, T. BCR/ABL Recruits p53 Tumor Suppressor Protein to Induce Drug Resistance. Cell Cycle, 3: 1463-1472, 2004.
Nowicki, M.O., Falinski, R., Koptyra, M., Slupianek A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J. and Skorski, T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species - dependent DNA double-strand breaks. Blood, 104: 3746-3753, 2004.
Majsterek, I., Slupianek A., Hoser, G., Skorski, T. and Blasiak J. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Biochimie, 86: 53-65, 2004.
Chipitsyna, G., Slonina, D., Siddiqui, K., Peruxzi, F., Skorski, T., Reiss, K., Sawaya, B.E., Khalili, K. and Amini, S. HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression. Oncogene, 23: 2664-2671, 2004.
Trojanek, J., HO, T., Wang, J.J., Del Valle, L., Lassak, A., Nowicki, M., Khalili, K., Skorski, T. and Reiss, K. Role of IGF-I/IRS-1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol. Cell. Biol., 23: 7510-7524, 2003.
Canitrot Y., Falinski, R., Louat, T., Laurent, G., Cazaux, C., Hoffmann, J-S., Lautier, D. and Skorski, T. p210BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood, 102: 2632-2637, 2003.
Nowicki, O.M., Pawlowski, P., Fisher, T., Hess, G., Pawlowski, T. and Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene, 2003, 22: 3952-3963, 2003.
Hoser, G., Majsterek, I., Romana, D.L., Slupianek A., Blasiak, J. and Skorski, T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leuk. Res., 27: 267-273, 2003.
Skorski, T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene, 21: 8591-8604, 2002.
Klejman, A., Schreiner, S.J., Nieborowska-Skorska, M., Slupianek, A., Wilson, M., Smithgall, T.E. and Skorski, T. The Src-family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J., 21: 5766-5774, 2002.
Blasiak, J., Gloc, E., Mlynarski, W., Drzewoski, J. and Skorski, T. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leuk. Res., 26: 1093-1096, 2002.
Blasiak, J., Gloc, E., Wozniak, K., Mlynarski, W., Stolarska, M., Skorski, T. and Majsterek, I. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem. Biol. Interact., 140: 1-18, 2002.
Majsterek, I., Blasiak, J., Mlynarski, W., Hoser, G. and Skorski, T. Does the BCR/ABL-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biol. Int., 26: 363-370, 2002.
Skorski, T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev. Cancer, 2: 351-360, 2002.
Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., Fishel, R. and Skorski, T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol. Cell. Biol., 22: 4189-4201, 2002.
Blasiak, J., Gloc, E., Wozniak, K., Mlynarski, W., Stolarska, M., Skorski, T. and Majsterek, I. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chemic. Biol. Interact., 140: 1-18, 2002.
Gloc, E., Warszawski, J., Mlynarski, W., Stolarska, M., Hoser, G., Skorski, T. and Blasiak, J. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Acta Biol. Pol., 49: 121-128, 2002.
Klejman, A., Rushen, L., Morrione, A., Slupianek, A. and Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene, 21: 5868-5876, 2002.
Zhang, Q., Raghunath, P.N., Xue, L., Majewski, M., Carpentieri, D.F., Odum, N., Morris, S., Skorski,T. and Wasik, M.A. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase- positive T/null-cell lymphoma. J. Immunol., 168: 466-474, 2002.
Nieborowska-Skorska, M., Hoser, G., Kossev, P., Wasik, M.A. and Skorski, T. Complementary functions of the anti-apoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL- mediated leukemogenesis. Blood, 99: 4531-4539, 2002.
Slupianek, A., Schmutte, C., Tombline, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M.O., Pierce, A.J., Fishel, R. and Skorski, T. BCR/ABL regulates the expression and nuclear localization of RAD51 to control therapeutic drug resistance. Mol. Cell, 8: 795-806, 2001.
Wang, Q., Zhang, H., Guerrette, S., Mazurek, A., Wilson, T., Slupianek, A., Skorski, T., Fishel, R., and Green, M.I. Adenosine nucleotide modulated signaling between hMSH2 and BRCA1. Oncogene, 20: 4640-4649, 2001.
Nieborowska-Skorska, M., Slupianek, A., Zhang, Q., Xue, L., Morris, S.W., Wasik, M.A., and Skorski,T. Role of STAT5 in NPM/ALK-mediated malignant transformation of lymphoid cells. Cancer Res.,61: 6517-6523, 2001.
Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., Morris, S.W., Wasik, M.A., and Skorski, T*. Role of PI-3k-Akt pathway in NPM/ALK-mediated lymphomagenesis. Cancer Research, 61:2194-2199, 2001.
Nieborowska-Skorska, M., Slupianek, A., Skorski, T.* Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells. Oncogene, 19:4117-4124, 2000.
Majewski, M., Nieborowska-Skorska, M., Salomoni, P., Slupianek, A., Reiss, K., Trotta, R., Calabretta, B., Skorski, T.* Activation of mitochrondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res., 59:2815-2819, 1999.
Nieborowska-Skorska, M., Wasik, M.A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., Skorski, T.* Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med., 189:1229-1242, 1999.
Iozzo, R.V., Charkani, F., Perrotti, D., McQuillan, D.J., Skorski, T., Calabretta, B., Eichstetter, I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl. Acad. Sci. USA, 96:3092-3097, 1999.
Ratajczak, M.Z., Skorski, T., Kuczynski, W., Ratajczak, J. Storage of human bone marrow before transplantation at 4 degrees C. The effect of cell proliferation potential particularly in hematopoietic cloned cell lines. Pol. Merkuruisz Lek., 4:143-146, 1998.
Skorski, T., Wlodarski, P., Daheron, L., Salomoni, P., Nieborowska-Skorska, M., Majewski, M., Wasik, M., and Calabretta, B. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Sci USA, 95:11858-11862, 1998.
Kawiak, J., Hoser, G. and Skorski, T. Apoptosis and some of its medical implications. Folia Histochem. Cytobiol., 36:99-110, 1998.
Perrotti, D., Bonatti, S., Trotta, R., Martinez, R., Skorski, T., Salomoni, P., Grassilli, E., Ioozzo, R.V., Cooper, D.R. and Calabretta, B. TLS/FUS, a protoconogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J., 17:4442- 4455, 1998.
Salomoni, P., Wasik, M.A., Riedel, R.F., Peiss, K., Choi, J.K., Skorski, T. and Calabretta, B.: Expression of constitutively active Raf-1 in the mitochondria restores anti-apoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J. Exp. Med., 187:1995- 2007, 1998.
Wlodarski, P., Wasik, M.A., Ratajczak, M.Z., Sevignani, C., Hoser, G., Kawiak, J., Gewirtz, A.M., Calabretta, B., Skorski, T.:* Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood, 91:2998-3006,1998.
Skorski, T.,* Nieborowska-Skorska, M., Wlodarski, P., Wasik, M.A., Trotta, R., Kanakaraj, P., Salomoni, P., Antonyak, M., Wasik, M., Martinez, R., Majewski, M., Wong, A., Perussia, B., Calabretta, B.: The SH3 domain contributes to BCR/ABL-mediated leukemogenesis in vivo: role in adhesion, invasion and homing. Blood, 91: 1-14, 1998.
Skorski, T.*, Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T.O., Wasik, M.A., Tsichlis, P., Calabretta, B.: Transformation of hematopoietic cells by BCR/ABL requires activation of PI-3k/Akt-dependent pathway. EMBO J., 16: 6151-6161, 1997.
DeFabritis, P., Skorski, T., Paggi, M.G., Nieborowska-Skorska, M., Lisci, A., DePropns, M.S., Buffolino, S., Campbell, K., Geiser, T., Mandelli, F. and Calabretta, B.: BCR-ABL oligonucleotides on CML-chronic phase colony formation increased specificity of anti-leuekmic effect through prologned incubations and the use of CD34-positive cells. Leukemia, 11:811-819,1997.
Santra, M., Mann, D.M., Mercer, E.W., Skorski, T., Calabretta, B., and Iozzo, R.V.: Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogeneic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest., 100:149-157, 1997.
Calabretta, B., and Skorski, T.: Targeting c-myc in leukemia. Anti-Cancer Drug Design, 12:373-381, 1997.
Skorski, T., Perrotti, D., Nieborowska-Skorska, M., Gryaznov, S., and Calabretta, B.: Antileukemia effect of c-myc N3’ - P5’ phosphoramidate antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA, 94:3966-3971, 1997.
Skorski, T.,* Nieborowska-Skorska, M., Wlodarski, P., Perrotti, D., Hoser, G., Kawiak, J., Majewski, M., Christensen, L., Iozzo, R.V., Calabretta, B.: Treatment of Philadelphia1 leukemia in SCID mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J. Natl. Cancer Inst., 89, 124-133, 1997.
Calabretta, B., Skorski, T.: Gene regulatory operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Critical Rev. Eukariot. Gene Expr., 7:117-124, 1997.
Skorski, T., Nieborowska-Skorska, M., Szczylik, C. and Calabretta, B.: Antisense oligonucleotides: from the bench to the patient. Biotechnology,4:108-115, 1996.
Szczylik, C., Skorski, T., Malaguanera, L., Hetman, J., Chen, S.T. and Calabretta, B.: Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides. Folia Histochem. Cytobiol., 34:129-134, 1996.
Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perotti, D., Wasik, M., Calabretta, B.: BCR/ABL oncogenic tyrosine kinase induces blastic transformation of p53 deficient bone marrow cells. Proc. Natl. Acad. SCi. USA, 93:13137-13142, 1996.
Calabretta, B., Skorski, T.: BCR/ABL activation of phosphatidylinositol-3 kinase. Leuk. Lymph.,23:473-476, 1996.
Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Zon, G., Iozzo, R.V., Calabretta, B.: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood, 88: 1005-1012, 1996.
Nieborowska-Skorska, M., Bialek, A.P., Nicolaides, N.C., Iozzo, R.V., Kawalec, M., Calabretta, B., Marlicz, K., Skorski, T.*: The influence of phosphorotioate oligodeoxynucleotides on various organs in vivo. Folia Histochem. Cytobiol., 34: 69-73, 1996.
Calabretta, B., Skorski, T., Ratajczak, M.Z., Gewirtz, A.M.: Antisense strategies in the treatment of leukemias. Semin. Oncol., 23: 78-87, 1996.
Gryaznov, S. Skorski, T., Cucco, C., Nieborowska-Skorska, M., Ying Chiu, C., Lloyd, D. Chen, J-K., Koziolkiewicz, M., Calabretta, B.: Oligodeoxynucleotide N3’--P5’ phosphoramidates as antisense agents. Nucl. Acids Res., 24: 1508-1514, 1996.
Fertala, J., Nieborowska-Skorska, M., Calabretta, B., Skorski, T.*: The diverse effect of topoiesomerase I specific inhibitor (camptothecin) on normal and BCR/ABL-dependent hematopoietic cells proliferation: therapeutic implications. Folia Histochem. Cytobiol., 33: 187-192, 1995.
Bialek, A.P., Skorski, T.*: Side effects after parenteral administration of antisense oligodeoxynucleotides. Post. Biol. Kom., 22: 415-425, 1995.
Ratajczak, M.Z., Kuczynski, W. I., Skorski, T., Ratajczak, J.: Pre-stimulation of the human bone marrow CD34+ cells before storage at 4oC with the early acting cytokines enhance their survival and increase proliferative potential. Transplantological implications. Mat. Med. Pol., 87: 133-136, 1995.
Skorski, T.*: Progress in molecular biology of leukemias - clinical implications. Acta Haematol. Pol.,26: 14-18, 1995.
Perottti, D., Melotti, P., Skorski, T., Casella, I., Peschle, C., Calabretta, B.: Overexpression of the zinc finger portein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation in the negative regulation of CD34 and c-myb promoter activity. Mol. Cell. Biol., 19: 6075-6087, 1995.
Salomoni, P., Wasik, M.A., Riedel, R.F., Peiss, K., Choi, J.K., Skorski, T. and Calabretta, B.: Expression of constitutively active Raf-1 in the mitochondria restores anti-apoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J. Exp. Med., 187:1995- 2007, 1998.
Wlodarski, P., Wasik, M.A., Ratajczak, M.Z., Sevignani, C., Hoser, G., Kawiak, J., Gewirtz, A.M., Calabretta, B., Skorski, T.:* Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood, 91:2998-3006,1998.
Skorski, T.,* Nieborowska-Skorska, M., Wlodarski, P., Wasik, M.A., Trotta, R., Kanakaraj, P., Salomoni, P., Antonyak, M., Wasik, M., Martinez, R., Majewski, M., Wong, A., Perussia, B., Calabretta, B.: The SH3 domain contributes to BCR/ABL-mediated leukemogenesis in vivo: role in adhesion, invasion and homing. Blood, 91: 1-14, 1998.
Skorski, T.*, Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T.O., Wasik, M.A., Tsichlis, P., Calabretta, B.: Transformation of hematopoietic cells by BCR/ABL requires activation of PI-3k/Akt-dependent pathway. EMBO J., 16: 6151-6161, 1997.
DeFabritis, P., Skorski, T., Paggi, M.G., Nieborowska-Skorska, M., Lisci, A., DePropns, M.S., Buffolino, S., Campbell, K., Geiser, T., Mandelli, F. and Calabretta, B.: BCR-ABL oligonucleotides on CML-chronic phase colony formation increased specificity of anti-leuekmic effect through prologned incubations and the use of CD34-positive cells. Leukemia, 11:811-819,1997.
Santra, M., Mann, D.M., Mercer, E.W., Skorski, T., Calabretta, B., and Iozzo, R.V.: Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogeneic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest., 100:149-157, 1997.
Calabretta, B., and Skorski, T.: Targeting c-myc in leukemia. Anti-Cancer Drug Design, 12:373-381, 1997.
Skorski, T., Perrotti, D., Nieborowska-Skorska, M., Gryaznov, S., and Calabretta, B.: Antileukemia effect of c-myc N3’ - P5’ phosphoramidate antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA, 94:3966-3971, 1997.
Skorski, T.,* Nieborowska-Skorska, M., Wlodarski, P., Perrotti, D., Hoser, G., Kawiak, J., Majewski, M., Christensen, L., Iozzo, R.V., Calabretta, B.: Treatment of Philadelphia1 leukemia in SCID mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J. Natl. Cancer Inst., 89, 124-133, 1997.
Calabretta, B., Skorski, T.: Gene regulatory operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Critical Rev. Eukariot. Gene Expr., 7:117-124, 1997.
Skorski, T., Nieborowska-Skorska, M., Szczylik, C. and Calabretta, B.: Antisense oligonucleotides: from the bench to the patient. Biotechnology,4:108-115, 1996.
Szczylik, C., Skorski, T., Malaguanera, L., Hetman, J., Chen, S.T. and Calabretta, B.: Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides. Folia Histochem. Cytobiol., 34:129-134, 1996.
Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perotti, D., Wasik, M., Calabretta, B.: BCR/ABL oncogenic tyrosine kinase induces blastic transformation of p53 deficient bone marrow cells. Proc. Natl. Acad. SCi. USA, 93:13137-13142, 1996.
Calabretta, B., Skorski, T.: BCR/ABL activation of phosphatidylinositol-3 kinase. Leuk. Lymph., 23:473-476, 1996.
Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Zon, G., Iozzo, R.V., Calabretta, B.: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood, 88: 1005-1012, 1996.
Nieborowska-Skorska, M., Bialek, A.P., Nicolaides, N.C., Iozzo, R.V., Kawalec, M., Calabretta, B., Marlicz, K., Skorski, T.*: The influence of phosphorotioate oligodeoxynucleotides on various organs in vivo. Folia Histochem. Cytobiol., 34: 69-73, 1996.
Calabretta, B., Skorski, T., Ratajczak, M.Z., Gewirtz, A.M.: Antisense strategies in the treatment of leukemias. Semin. Oncol., 23: 78-87, 1996.
Gryaznov, S. Skorski, T., Cucco, C., Nieborowska-Skorska, M., Ying Chiu, C., Lloyd, D. Chen, J-K., Koziolkiewicz, M., Calabretta, B.: Oligodeoxynucleotide N3’--P5’ phosphoramidates as antisense agents. Nucl. Acids Res., 24: 1508-1514, 1996.
Fertala, J., Nieborowska-Skorska, M., Calabretta, B., Skorski, T.*: The diverse effect of topoiesomerase I specific inhibitor (camptothecin) on normal and BCR/ABL-dependent hematopoietic cells proliferation: therapeutic implications. Folia Histochem. Cytobiol., 33: 187-192, 1995.
Bialek, A.P., Skorski, T.*: Side effects after parenteral administration of antisense oligodeoxynucleotides. Post. Biol. Kom., 22: 415-425, 1995.
Ratajczak, M.Z., Kuczynski, W. I., Skorski, T., Ratajczak, J.: Pre-stimulation of the human bone marrow CD34+ cells before storage at 4oC with the early acting cytokines enhance their survival and increase proliferative potential. Transplantological implications. Mat. Med. Pol., 87: 133-136, 1995.
Skorski, T.*: Progress in molecular biology of leukemias - clinical implications. Acta Haematol. Pol.,26: 14-18, 1995.
Perottti, D., Melotti, P., Skorski, T., Casella, I., Peschle, C., Calabretta, B.: Overexpression of the zinc finger portein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation in the negative regulation of CD34 and c-myb promoter activity. Mol. Cell. Biol., 19: 6075-6087, 1995.
Skorski, T., Nieborowska-Skorska, M., Iozzo, R.V., Campbell, K., Zon, G., Darzynkiewicz, Z., Calabretta B.: Leukemia treatment in SCID mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J. Exp. Med., 182: 1645-1653, 1995.
Ratajczak, M.Z., Marlicz, W., Ratajczak, J., Skorski, T.*: Characterization, isolation and practical aspects of utilization of human early hematopoietic cells in clinical medicine - transplantological implications. Post. Biol. Kom., 22: 209-234, 1995.
Santra, M., Skorski, T., Calabretta, B., Lattime E.C., Iozzo, R.V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA, 92: 7016-7020, 1995.
Skorski, T., Nieborowska-Skorska, M., Szczylik, C., Kanakaraj, P., Perotti, D., Zon, G., Gewirtz, A., Perussia, B., Calabretta, B. c-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res., 55: 2275-2278, 1995.
Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M.Z., Wen, S-C., Zon, G., Gewirtz, A.M., Perussia, B., Calabretta, B.: Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 86: 726-736, 1995.
Ratajczak, M.Z., Skorski, T., Bialek, A.: The perspectives of the application of antisense oligodeoxynucleotides in the clinical trials. Biotechnology, 28: 35-43,1995.
Skorski, T.,* Nieborowska-Skorska, M.: The application of antisense oligodeoxynucleotides for the investigations of the molecular mechanisms activated by oncogenes: therapeutical implications. Biotechnology, 28: 44-53,1995.
Nieborowska-Skorska, M., Ratajczak, M.Z., Calabretta, B., Skorski, T.*: The role of c-MYC in chronic myeloid leukemia. Folia Histochem. Cytobiol., 32: 231-234, 1994.
Ratajczak, M.Z., Skorski, T.*: The perspectives of antisense strategy application in the experimental and clinical medicine. Post. Biol. Kom., 21: 177-196, 1994.
Ratajczak, M.Z., Ratajczak, J., Kregenov, D., Skorski, T., Kuczynski, W., Gewirtz, A.M.: Cytokine stimulation of the CD34+ bone marrow cells prior to cryopreservation enhances their post-thawing proliferative potential. Folia Histochem. Cytobiol., 32: 145-149, 1994.
Skorski, T.*: Molecular basis of chronic granulocytic leukemia: from the bench to the patient. Acta Haematol. Pol., 25(1):184-191, 1994.
Skorski, T., Kanakaraj, P., Ku, D.H., Nieborowska-Skorska, M., Canaani, E., Perussia, B., Calabretta, B.: Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth. J. Exp. Med., 179:1855-1865, 1994.
Skorski, T., Nieborowska-Skorska, M., Nicolaides, N., Szczylik, C., Iversen, P., Iozzo, R.V., Zon, G., Calabretta, B.: Suppression of Philadelphia1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 91:4504-4508, 1994.
Ratajczak M.Z., Ratajczak J., Kuczynski W.I., Skorski T.: In-vitro study on anaemia in chronic inflamatory conditions. Effect of recombined interleukin-1β on human erythropoiesis. Pol. Arch. Med. Wewn., 91:97-104, 1994.
Nieborowska-Skorska, M., Nakashima, M., Ratajczak, M., Steplewski, Z., Calabretta, B., Skorski, T.*: Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment. Folia Histochem. Cytobiol., 32:35-40, 1994.
Smetsers, T.F.C.M., Skorski, T., Van der Locht, L.T.F., Wessels, M.M.C., Pennings, A.H.M., de Witte, T., Calabretta, B., Mensink, E.J.B.M.: Antisense BCR-ABL oligodeoxynucleotides induce apoptosis in the Philadelphia chromosome positive cell line BV173. Leukemia, 8:129-140, 1994.
Ratajczak, M.Z., Kuczynski, W., Skorski, T., Ratajczak, J.: Pre-stimulation of the human bone marrow CD34+ cells before storage at 4oC with the early acting cytokines enhance their survival and increase proliferative potential. Transplantological implications. Materia Medica Polona, 3-4: 1-4, 1993.
Calabretta, B., Nieborowska-Skorska, M., Skorski, T.: Inhibition of Philadelphia1 leukemia cell growth by bcr/abl antisense oligonucleotides. Cancer Chemother., 8:19-28, 1993.
Ratajczak, M.Z., Skorski, T., Kuczynski, W., Ratajczak, J.: The influence of 4∞C storage on proliferative potential of human bone marrow CD34+ cells. Transplantological implications. Folia Histochem. Cytobiol., 31:109-112, 1993.
Nieborowska-Skorska, M., Skorski, T., Ratajczak, M.Z., Szczylik, C., Kawalec, M., Malaguarnera, L., Kawiak, J., Calabretta, B.: Successful mafosfamide purging at bone marrow from chronic myelogenous leukemia (CML) cells. Folia Histochem. Cytobiol., 31:161-167, 1993.
Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M., Szczylik, C., Arlinghaus, R.B., Gerwirtz, A., Perussia, B., Calabretta, B.: p120 GAP requirement in normal and malignant human hematopoiesis. J. Exp. Med., 178:1923-1933, 1993.
Szczylik, C., Skorski, T., Ku, D-H., Nicolaides, N.C., Wen, S-C., Rudnicka, L., Bonati, A., Malaguarnera, L., Calabretta, B.: C-myb regulation of marrow fibroblasts proliferation and cytokine expression. J. Exp. Med., 178:997-1005, 1993.
Kawalec, M., Hoser, G., Skorski, T., Kawiak, J.: Immunogenic and nondividing mafosfamide-treated L1210 cells - comparison of lines resistant and nonresistant to cyclophosphamide. Folia Histochem. Cytobiol., 31:63-66, 1993.
Skorski, T., Nieborowska-Skorska, M., Barletta,C., Malaguarnera, L., Szczylik, C., Chen, S.T., Lange, B., Calabretta, B.: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest., 92:194-202, 1993.
Calabretta, B., Skorski, T., Szczylik, C., Zon, G.: Prospects for gene-directed therapy with antisense oligodeoxynucleotides. Cancer Treat. Rev., 19:169-179, 1993.
Calabretta, B., Skorski, T., Zon, G.: Antisense oligonucleotides. Semin. Cancer Biol., 3:391-398, 1992.
Calabretta, B., Skorski, T., Szczylik, C., Caracciolo, D., Valtieri, M. and Venturelli, D.: Protooncogenes in the regulation of normal hematopoiesis: an antisense approach. Ann. N.Y. Acad. Sci. USA, 660:117-123, 1992.
Skorski, T.*, Nieborowska-Skorska, N., Calabretta, B.: A model of Ph'-positive chronic myeloid leukemia-blast crisis cell line growth in immune deficient SCID mice. Folia Histochem. Cytobiol., 30:91-96, 1992.
Raschella, G., Negroni, A., Skorski, T., Pucci, S., Nieborowska-Skorska, M., Romeo, A. and Calabretta B.: Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines. Cancer Res., 52:4221-4226, 1992.
Skorski, T., Szczylik, C., Ratajczak, M.Z., Malaguarnera, L., Gewirtz, A.M. and Calabretta. B.: Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J. Exp. Med., 175:743-750, 1992.
Ratajczak, M.Z. and Skorski, T.*: The possible application of oligodeoxynucleotides in clinical oncology. Pol Tyg. Lek., XLVI:913-917, 1992.
Szczylik, C., Skorski, T., Nicolaides, N.C., Manzella, L., Malaguarnera, L., Venturelli, D., Gewirtz, A.M. and Calabretta, B.: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science, 253:562-565, 1991.
Skorski, T.,* Ratajczak, M.Z., Kawalec, M. and Kawiak, J.: Induction of immune resistance against L1210 lymphatic leukemia in mice after lethal irradiation and reconstitution with fetal liver cells. Folia Histochem. Cytobiol., 29:121-124, 1991.
Skorski, T.,* Szczylik, C., Malaguarnera, L. and Calabretta, B.: Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem. Cytobiol., 29:85-90, 1991.
Kawalec, M., Hoser, G., Miks, B., Skorski, T., Pojda, Z. and Skurzak, H.: Changes of thymocyte subpopulations induces by activities diffusing from leukemia L1210 cells. Thymus, 18:185-192, 1991.
Skorski, T.,* Kawalec, M. and Kawiak, J.: Early induction of immune resistance against leukemia in mice after lethal irradiation followed by syngeneic bone marrow transplantation and injection of syngeneic leukocytes. Transplantation, 51:843-847, 1991.
Skorski, T.,* Kawalec, M. and Kawiak, J.: Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukemia with mafosfamide. Cancer Immunol. Immunother., 32:71-74, 1990.
Skorski, T.,* Kawalec, M., Ratajczak, M.Z., Szczylik, C. and Kawiak, J.: Return of immunohematopoietic impairment a long time after murine syngeneic bone marrow transplantation. Bone Marrow Transplant., 6:315-319, 1990.
Skorski, T.,* Kawalec, M. and Kawiak, J.: Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice. Bone Marrow Transpl., 2:23-27, 1990.
Skorski, T.,* Kawalec, M. and Kawiak, J.: A simple method of bone marrow cryopreservation. Folia Histochem. Cytobiol., 27:67-72, 1989.
Nieborowska-Skorska, M. and Skorski, T.*: The use of autologous bone marrow grafts in the treatment of neoplasma. Wiad. Lek., 6:383-389, 1988.
Kawalec, M., Skorski, T., Hoser, G.: Immunogenicity of cyclophosphamide-treated tumor cells. Arch. Immunol. Ther. Exptl., 36:345.-350, 1988.
Ratajczak, M.Z., Urbanowska, E., Skorski, T., Kawalec, M. and Szczylik, C.: Hemopoietic and immunologic status in murine short and long term survivors after total body irradiation and transplantation of syngeneic bone marrow cells. Blut, 67:235, 1988.
Kawiak, J., Skorski, T., Ciechanowicz, A., Zylinska, M., Seidel, H.J., Kawalec, M., Gnatowski, B. and Czarnomska, A.: Cytochemical characterization of mouse L1210 leukemia. Immunol. Invest., 17:543-550, 1988.
Skorski, T.,* Kawalec, M., Hoser, G., Ratajczak, M. Gnatowski, B. and Kawiak, J.: The kinetics of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (ASTA Z7654). Bone Marrow Transpl., 3:543-551, 1988.
Skorski, T.,* and Kawalec, M.: Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide. Exp. Hematol., 16:782-784, 1988.
Kawalec, M., Skorski, T. and Kawiak, J.: Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells. Invest. New Drugs, 6:169-172, 1988.
Skorski, T.,* and Kawalec, M.: Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z7654). Bone Marrow Transpl., 2:435- 440, 1987.
Skorski, T.,*and Kawalec, M.: New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z7654) - immunogenic properties of lymphatic leukemia L1210 cells treated in vitro with the drug. Invest. New Drugs, 5:167-169, 1987.
Skorski, T.,* Kawalec, M. and Kawiak, J.: Cellular composition of spleen and peritoneal exudate in mice after injection of cyclophosphamide-treatment L1210 leukemia cells. Folia Histochem. Cytobiol., 24:23-28, 1987.
Skorski, T.,* Kawalec, M. and Kawiak, J.: Mechanisms of immunological response induced in CD2F1 mice by administration of semisyngeneic L1210 leukemia cells treated with cyclophosphamide. Immunol. Invest., 16:33-43, 1987.
Skorski, T.*: Lymphocytes B and T: Characterization, stimulation of activity and role in the overcoming of tumors. Post. Biol. Kom., 13:335-358, 1986.
Skorski, T.*: NK and K cells: Characterization stimulation of activity and role in the overcoming of tumors. Post. Biol. Kom., 13:51-74, 1986.
Skorski, T.*: Kawalec, M. and Hoser, G.: Cyclophosphamide- or ifosfamide-treated L1210 leukemia cells: immunogenicity, viability and metabolism. Folia Biol., (Praha), 32:354-365, 1986.
Skorski, T.*: The role of macrophages, monocytes and granulocytes in the overcoming of tumors. Post. Biol. Kom., 12:185-203, 1985.
Skorski, T.*: The role of the BCG dose and the mouse strain in the inhibition of development of neoplasms susceptible and nonsusceptible to the action of natural cytotoxic cells. Folia Histochem. Cytobiol., 23:3-10, 1985.
Skorski, T.*: The changes in the population of mouse peritoneal exudate cells (PEC) after intraperitoneal injection of BCG. Folia Histochem. Cytobiol., 22:240-241, 1984.
Kawalec, M., Jakobisiak, M., Skorski, T. and Kawiak, J: Immunogenicity of cyclophosphamied- treated leukemia cells. Folia Biol. (Praha), 28:334-343, 1982.
Skorski, T.*: Regulation of NK cells cytotoxic activity. Post. Biol. Kom., 9:475-502, 1982.